CORE--VECTOR

核心--向量

• 批准号: 6658441
• 负责人: Stephen M. Kaminsky
• 金额: $ 12.63万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6658441
• 关键词: Adenoviridae; Lentivirus; Retroviridae; adeno associated virus group; biomedical facility; biotechnology; herpes simplex virus 1; liposomes; microorganism culture; plasmids; transfection /expression vector

DESCRIPTION (provided by applicant): The Vector Core designs, constructs, produces and characterizes all the plasmid, adenovirus, adenoassociated virus, retrovirus, and lentivirus vectors required by the projects. Based in the 12,000 ft2 Belfer Gene Therapy Core Facility (GTCF), the Vector core is assigned 2600 ft2 of newly renovated, fully equipped research space. The Vector Core, co-directed by Stephen Kaminsky, PhD (DNA Vectors) and Robert Pergolizzi, PhD (RNA Vectors) will provide state-of- the-art resources for the design, construction and purification of laboratory grade vectors for in vitro and in vivo applications in all four projects in this proposal. The Core has the capability to provide high quality verified reagents to investigators on a large scale. The Core has trained personnel with extensive experience in all areas of vector development, vector production, and gene transfer who will collaborate with investigators as needed to adopt new technologies for gene transfer as they emerge. Standard operating procedure and biological materials with a descriptive database are available to expedite progress in the projects. The Core staff will participate in the education and training of investigators in the technology of vector production and characterization.

描述（由申请人提供）： 矢量核心设计，构造，产生和表征项目所需的所有质粒，腺病毒，腺病毒，腺病毒，逆转录病毒和慢病毒矢量。基于12,000 FT2 BELFER基因治疗核心设施（GTCF），向量核心分配了2600 FT2新装修，设备齐全的研究空间。由Stephen Kaminsky（DNA矢量）和Robert Pergolizzi（RNA矢量）共同导演的矢量核心将为该提案中所有四个项目中的体外和Vivo应用程序的实验室级别设计，构建和纯化实验室级矢量提供最新资源。核心有能力向研究人员提供高质量验证的试剂。核心在媒介发展，向量生产和基因转移方面拥有丰富经验的核心人员，他们将根据需要与调查人员合作，以在出现时采用新技术进行基因转移。具有描述性数据库的标准操作程序和生物材料可在项目中加快进度。核心人员将参加研究人员在向量生产和表征技术方面的教育和培训。